Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II/III global first-line NSCLC study of BNT327 (PM8002) plus chemotherapy and other study drugs
CTR20263000Phase 3Active
- Sponsor
- Biotheus
- Start
- Aug 2026
- Modality
- Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 3 trial of pumitamig in non-small cell lung cancer (NSCLC), sponsored by Biotheus. Started Aug 2026; status: active.
02
Drugs
pumitamig
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on CTR20263000.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20263000.